Clinical Study
Intradiverticular Ampulla of Vater: Personal Experience at ERCP
| | | Group A
| Group B
| |
| | Successful cannulation | 81/81 (100%) | 412/419 (98%) | 0.2 (ns) | | Difficult cannulation (Boix scale) | | | | | Grade I | 6/81 (7.4%) | 353/419 (84.2%) | <0.05 | | Grade II | 72/81 (88.9%) | 53/419 (12.6%) | <0.05 | | Grade III | 3/81 (3.7%) | 6/419 (1.4%) | 0.16 (ns) | | Grade IV | 0 | 7/419 (1.7%) | 0.24 (ns) | | CBD stones > 10 mm | 13/81 (16.1%) | 61/419 (14.5%) | 0.72 (ns) | | Biliary sludge and microstones | 27/81 (33.3%) | 68/419 (16.2%) | <0.005 | | Ampulloma/ampullary cancer | 0 | 21/419 (5.0%) | 0.07 (ns) | | Biliary hilar cancer (Klatskin) | 3/81 (3.7%) | 31/419 (7.4%) | 0.22 (ns) | | Pancreatic cancer | 0 | 48/419 (11.4%) | <0.005 | Cholangiographic abnormalities
(stones, strictures, dilation) | 51/81 (62.9%) | 398/419 (95%) | <0.005 | | Dilated CBD without stones | 30/81 (37.1%) | 21/419 (5.0%) | <0.005 | | Other (liver metastasis, hemobilia) | 2/81 (5.5%) | 6/419 (1.4%) | 0.49 (ns) | | Complications | | | | | Clinical bleeding | 1/81 (1.2%) | 15/419 (3.6%) | 0.27 (ns) | | Perforation | 0 | 2/419 (0.5%) | 0.53 (ns) | | Pancreatitis | 2/81 (2.4%) | 12/419 (2.9%) | 0.84 (ns) | | Cholecystitis | 0 | 0 | na | | Death (ERCP related) | 0 | 0 | na | | Immediate bleeding | 1/81 (1.2%) | 14/419 (3.3%) | 0.31 (ns) | | Hyperamylasemia | 52/81 (64.2%) | 106/419 (25.3%) | <0.005 | | CBD stone recurrence at followup | 53/81 (65.4%) | 38/419 (9.1%) | <0.005 |
|
|
ns: not significative; na: not applicable; CBD: common bile duct.
|
